Implantable medical device with anti-infection agent

Information

  • Patent Grant
  • 8086313
  • Patent Number
    8,086,313
  • Date Filed
    Wednesday, August 5, 2009
    15 years ago
  • Date Issued
    Tuesday, December 27, 2011
    13 years ago
Abstract
An implantable medical device comprises an anti-infection agent. The implantable medical device may be configured for placement in the head of a patient and for monitoring or treatment of the brain. The implantable medical device may have a housing or it may have a housing and a member for providing a smooth interface between the device and the adjacent tissue. The anti-infection agent may be provided on or impregnated in the housing or the member. In some embodiments, the device includes a single module while in other embodiments a plurality of modules are coupled to provide a smaller profile. In some embodiments the implantable medical device may include both anti-infection and lubricious materials.
Description
TECHNICAL FIELD

The invention relates to medical devices, and more particularly, to implantable medical devices that deliver therapy to and/or monitor a patient.


BACKGROUND

Implantable medical devices (IMD's) carry the risk of causing infection in the patient. Bacteria on the surface of the IMD can result in serious patient problems.


It is desirable to implant IMD's near the site of treatment (e.g., in the head when the IMD is a brain stimulator). These remote locations often provide spaces that are either small or shaped in such a way that traditional IMD's do not fit therein or for which it is desirable to create a smooth interface with the surrounding tissue. Different configurations of IMD's may be devised to better fit into these spaces. However, these different configurations raise questions about the possibility of increased infection.


SUMMARY

In general, the invention relates to an implantable medical device including an anti-infection agent on the external surface or impregnated in the external surface for reducing the likelihood of infection.


Various embodiments of the invention are presented including a device for implantation in the head of a patient. Some more specific embodiments configure the device for implantation between the cranium and the scalp.


Various embodiments also include a member coupled to the module or modules for providing a smooth interface between the device and adjacent tissue. An anti-infection agent is on or impregnated in the member.


Various other embodiments also include a member coupled to the module or modules for providing a smooth interface between the device and the scalp or the tissue near the scalp. These embodiments include an anti-infection agent on or impregnated in the member. The member may be any material capable of providing a smooth interface with the tissue. The member can include elastomeric materials, such as silicone, and/or non-elastomeric materials such as polysulfone and polyurethane.


Various embodiments of the invention include a single module while other embodiments include a plurality of interconnected modules. These embodiments include an anti-infection agent on or impregnated in the housing or member.


Other embodiments include an implantable medical device including a lubricious material and an anti-infection agent. Methods of fabricating an implantable medical device including an anti-infection agent are also presented.


The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other embodiments of the invention will be apparent from the description and drawings, and from the claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a conceptual diagram illustrating one embodiment of an implantable medical device of the present invention.



FIG. 1B is a conceptual diagram illustrating another embodiment of an implantable medical device of the present invention.



FIGS. 1C and 1D are conceptual diagrams illustrating a modular implantable medical device implanted in a patient according to an example embodiment of the present invention.



FIG. 2 is a schematic diagram illustrating a modular implantable medical device according to another embodiment of the present invention.



FIGS. 3A-3F are schematic diagrams illustrating various arrangements of modules within a modular implantable medical device according to various embodiments of the present invention.



FIGS. 4A-4C are schematic diagrams illustrating the construction of a member of a modular implantable medical device according to the present invention.



FIGS. 5A-5B are schematic diagrams illustrating the interaction of components of a member according to the present invention.



FIG. 6 is a schematic diagram illustrating the degrees of motion present in a modular implantable medical device.



FIG. 7 is a schematic diagram illustrating motion reduction within various degrees of motion within a modular implantable medical device.



FIGS. 8A-8C are schematic diagrams illustrating example embodiments of modular implantable medical devices having lead management features.



FIG. 9 is a schematic diagram illustrating an example embodiment of a modular implantable medical device having an access loop for removal.



FIG. 10 is a schematic diagram illustrating a perspective view of an example embodiment of a modular implantable medical device having a triangular module arrangement.



FIG. 11 is a schematic diagram illustrating a perspective view of an example embodiment of a modular implantable medical device having an inline module arrangement.



FIG. 12 is a schematic diagram illustrating side view of a modular implantable medical device having an inline module arrangement.



FIG. 13 is a schematic diagram illustrating an exploded view of a modular implantable medical device having a triangular module arrangement.



FIG. 14 is a flowchart illustrating a method of constructing an implantable medical device with a member according to the present invention.



FIG. 15 is a flowchart illustrating a method of fabricating an implantable medical device including a lubricious material on or impregnated in the housing according to one embodiment of the present invention.



FIG. 16 is a flowchart illustrating a method of fabricating an implantable medical device including a lubricious material on a member according to one embodiment of the present invention.



FIG. 17 is a flowchart illustrating a method of fabricating an implantable medical device including an anti-infection agent on or impregnated in the housing according to one embodiment of the present invention.



FIG. 18 is a flowchart illustrating a method of fabricating an implantable medical device including an anti-infection agent on or impregnated in a member according to one embodiment of the present invention.



FIGS. 19A-19B are schematic diagrams illustrating another embodiment of an implantable medical device.





DETAILED DESCRIPTION


FIG. 1A is a conceptual diagram of an implantable medical device 80 including housing 82 and therapy delivery element 84 (e.g., lead, catheter, extension and lead). An anti-infection agent and/or lubricious material as described herein, may be disposed on or impregnated in at least a portion of the implantable medical device 80. In one embodiment the anti-infection agent and/or lubricious material may be placed on the housing 82 in the form of a coating 86. Disposing an anti-infection agent and/or lubricious material on or impregnated in the device 80 may facilitate insertion of the device 80 into the implantable location within a human body. The anti-infection agent reduces the likelihood of infection. The lubricious material reduces friction between the device 80 and the tissue near the device 80. In cases where the implantable medical device is implanted in a tight space such as between the cranium and the scalp, the lubricious material may reduce the likelihood of skin erosion by decreasing the friction forces between the device and the scalp. A lubricious material may also minimize fibrous capsule growth around the device by lowering the friction between the device and the scalp. This would have the additional benefit of reducing the likelihood of infection.


For many therapies such as brain stimulation for movement disorders it may be desirable for the device to provide unipolar stimulation whereby the housing is used as an electrode. Therefore, in some embodiments it may be desirable to use a lubricious material that is electrically conductive or to apply the lubricious material to less than the entire housing.


In one embodiment, housing 82 includes at least a portion of the electronics for providing monitoring of or therapy to a patient. Some examples of implantable medical devices that include at least a portion of the electronics for providing monitoring of or therapy to a patient include implantable neurostimulators, implantable drug delivery pumps, pacemakers, defibrillators and monitoring devices that receive physiological signals from a patient and store or relay such information. Such devices that provide therapy to the patient may be open or closed loop devices (e.g., closed loop device receives sensed information and delivers therapy based on the sensed information).


Application of an anti-infection agent and/or lubricious material is also desirable in the case of a modular device having more than one module and housing. In such a case a one embodiment includes an anti-infection agent and/or lubricious material on at least a portion of both housings.


An implantable medical device may be implantable anywhere in the body. For example, the implantable medical device may be implanted in the abdomen, pectoral or buttock areas. An implantable medical device may also be implanted in the head of a patient such as between the cranium and the scalp. Other embodiments may include an implantable medical device for implantation partially or wholly within a groove or recess placed in the cranium.


As shown in FIG. 1B, an implantable medical device may be an implantable medical device 90 for implantation in the head of a patient. Device 90 may be placed between the cranium and the scalp. Device 90 includes housing 92, member 94 and therapy delivery element 96. Member 94 provides a substantially smooth interface between device 90 and the scalp or other tissue near the scalp. In one sub-embodiment of this embodiment, the member 94 partially encapsulates housing 92. An anti-infection agent and/or lubricious material may be disposed on or impregnated in the member 94. In one embodiment, the anti-infection agent and/or lubricious material is provided as a coating 98 on the member 94. In one embodiment the anti-infection agent and/or lubricious material 98 is only on the convex side of the member 94. Application of the lubricious material 98 to the convex side of the member 94 is desired to reduce friction between the convex side of the member 94 and the scalp or other tissue near the scalp. However, the lubricious material may also be applied to more than one side of the member 94. Application of the anti-infection agent may be over all or a part of the device. In a cranial application it may be desirable to apply the anti-infection agent to the concave side of the device or member.


In another embodiment the implantable medical device may be a modular implantable medical device. FIGS. 1C and 1D are conceptual diagrams illustrating a modular implantable medical device 101 implanted within a patient 100. By constructing modular implantable medical device 101 as a set of distributed modules connected together as described herein, modular implantable medical device 101 may be implanted at locations for which implantation of conventional implantable medical devices has been deemed undesirable, thus permitting the implantable medical device 101 to be implanted near a monitoring and/or therapy delivery location. In the example illustrated within FIGS. 1C-1D, modular implantable medical device 101 is implanted under the scalp of the patient 100 in order to locate the device 101 close to the location to which therapy is to be delivered via leads 102, i.e., the brain of patient 100. The low profile and the shape of modular implantable medical device 101 as described herein can reduce the risk of infection and skin erosion associated with implantation of matter beneath the scalp, and may provide a cosmetically acceptable profile when implanted beneath the scalp.


Modular implantable medical device 101 may deliver stimulation to the brain of patient 100 to, for example, provide deep brain stimulation (DBS) therapy, or to stimulate the cortex of the brain. Cortical stimulation may involve stimulation of the motor cortex. Modular implantable medical device 101 may be used to treat any nervous system disorder including, but not limited to, epilepsy, pain, psychological disorders including mood and anxiety disorders, movement disorders (MVD), such as, but not limited to, essential tremor, Parkinson's disease, and neurodegenerative disorders.


However, modular implantable medical device 101 is not limited to delivery of stimulation to the brain of patient 100, and may be employed with leads 102 deployed anywhere in the head or neck including, for example, leads deployed on or near the surface of the cranium, leads deployed beneath the cranium such as near or on the dura mater, leads placed adjacent cranial or other nerves in the neck or head, or leads placed directly on the surface of the brain. Moreover, modular implantable medical device 101 is not limited to implantation under the scalp of patient 100. Indeed, modular implantable medical device 101 may be implanted anywhere within patient 100. For example, modular implantable medical device 101 can be implanted within the neck of patient 100, and deliver stimulation to the vagus nerve or the cervical region of the spinal cord.


Modular implantable medical device 101 may alternatively be implanted within a pectoral region or the abdomen of patient 100 to act as a diaphragmatic pacer, or to provide any of the monitoring and therapy delivery functions known in the art to be associated with cardiac pacemakers. Further, modular implantable medical device 101 may be implanted in the upper buttock region and deliver spinal cord, urological or gastrological stimulation therapy, or may be configured to be implanted within the periphery, e.g., limbs, of patient 100 for delivery of stimulation to the muscles and/or peripheral nervous system of patient 100. As is the case with cranial implantation, the modularity of implantable medical device 101 may enable implantation at some of these example locations for which implantation of conventional implantable medical devices is generally deemed undesirable.


Modular implantable medical device 101 is not limited to embodiments that deliver stimulation. For example, in some embodiments modular implantable medical device 101 may additionally or alternatively monitor one or more physiological parameters and/or the activity of patient 100, and may include sensors for these purposes. Where a therapy is delivered, modular implantable medical device 101 may operate in an open loop mode (also referred to as non-responsive operation), or in a closed loop mode (also referred to as responsive). Modular implantable medical device 101 may also provide warnings based on the monitoring.


As discussed above, the ability of a modular implantable medical device 101 according to the invention to be implanted close to a region within patient 100 to be monitored enables the use of shorter leads 102. Shorter leads 102 may advantageously improve the accuracy of such sensors by reducing noise attributable to leads 102. Shorter leads 102 may also advantageously reduce the negative affects of imaging techniques such as magnetic resonance imaging “MRI” on a person implanted with implantable medical device 101.


Additional alternate embodiments for implantable medical devices implemented according to principles of the present invention may also include non-electrical based therapies such as targeted introduction of fluids and similar therapeutic materials using pumps and reservoirs of material. One skilled in the art will recognize that any number of implantable devices may be possible without deviating from the spirit and scope of the present invention as recited within the attached claims.



FIG. 2 is a schematic diagram illustrating a modular implantable medical device 201 according to another embodiment of the present invention. In this example embodiment, implantable medical device 201 is arranged in a triangular configuration. Modular implantable medical device 201 includes three modules: a control module 210, a power source module 211, and a recharge module 212. Each of modules 210-212 includes a respective housing. Modular implantable medical device 201 also contains a set of lead connection modules 213 that permits external leads 102 (FIGS. 1C and 1D) to be connected to control module 210 as needed. In this way, lead connection module 213 is configured to receive external leads 102 that are separate from lead connection module 213. The distribution of functional components of modular implantable medical device 201 into modules permits modular implantable medical device 201 to possess a thin profile by spreading the components over a larger surface area.


Control module 210 includes control electronics for controlling the monitoring and/or therapy delivery functions of modular implantable medical device 201, such as a microprocessor, and may include therapy delivery circuitry. Power source module 211 includes a power source that provides energy to control module 210, which in some embodiments is a rechargeable power source such as a rechargeable battery and/or capacitor. Recharge module 212 includes a recharge coil for inductively receiving energy to recharge a rechargeable power source within power source module 211.


In some embodiments, one or modules may be coupled by coupling modules (not shown). A coupling module may be flexible, and may include a lumen to carry a conductor or a fluid between modules of a modular implantable medical device. In some embodiments, a coupling module is made of a flexible material such as silicone or a flexible polymer. In other embodiments a coupling module is hermetic and made of substantially less flexible material, such as titanium or stainless steel, and the flexibility of a coupling module is provided by the configuration and/or construction the coupling module.


A coupling module may be flexible in a plurality of directions to provide modules of a modular implantable medical device with multiple degrees of freedom of motion with respect to each other. In exemplary embodiments, a coupling module provides at least three degrees of motion, and the degrees of motion provided include rotational motion.


Additional details regarding modules 210, 211 and 212, additional or alternative modules for a modular implantable medical device, the interconnection of modules within a modular implantable medical device, and lead connection modules 213 may be found in commonly assigned U.S. Patent Application Publication No. 2004/0176818 by Wahlstrand et al., entitled “MODULAR IMPLANTABLE MEDICAL DEVICE”; commonly assigned U.S. Pat. No. 7,848,817 to Janzig et al., entitled “COUPLING MODULE OF A MODULAR IMPLANTABLE MEDICAL DEVICE”; and commonly assigned U.S. Patent Application Publication No. 2004/0176816 by Singhal et al., entitled “LEAD CONNECTION MODULE OF A MODULAR IMPLANTABLE MEDICAL DEVICE.” As illustrated in FIG. 2, modular implantable medical device 201 includes a member 214. A member generally serves as a smooth interface between one or more modules and the body tissue.


A member may be made of any material. In one embodiment the member may be made of a metal. For example, a member may be made of titanium or of other biocompatible metals. In another embodiment, the member may be made of a soft, biocompatible material. In other embodiments the member may be made of multiple materials. An anti-infection agent and/or lubricious material 215 may be on or impregnated in a portion of the member 214 (for example, on the convex side of the member 214). Alternatively, the anti-infection agent and/or lubricious material 215 may be on or impregnated in the entire outer surface of the member 214.


Member 214 at least partially encapsulates modules 210-212. Further, as will be described in greater detail below, lead connection modules 213 may be formed in member 214. Member may integrate modules 210-212 into a structure. Member 214 may provide a flexible structure that permits the device 501 to conform to a variety of implant locations.


In some embodiments, member 214 may be curved to match the shape of the location within a patient in which the device is being implanted. For example, implantation of modular implantable medical device 201 under the scalp of a patient may be accomplished if member 214 is concave (as viewed from the cranium) to substantially conform to the shape of the cranium of the patient and convex (as viewed from the scalp) to provide a smooth interface with the scalp or tissue near the scalp and thus reduces the likelihood of skin erosion and other problems associated with edges or protrusions pushing against the scalp. Concavity of modular implantable medical devices is described in greater detail in a commonly-assigned U.S. Pat. No. 7,529,586 to Wahlstrand et al., entitled “CONCAVITY OF AN IMPLANTABLE MEDICAL DEVICE.” Any number of shapes may be used to match a particular implantable medical device 201 to an implantation location for a device.


Member 214 may comprise a solid biocompatible elastomeric material that is soft and flexible such as silicone. In some embodiments, member 214 comprises two or more materials, and two or more components. For example, member may comprise one or more elastomeric components formed of an elastomeric material, such as silicone, and one or more non-elastomeric components formed of a non-elastomeric material, such as polysulfone, or a polyurethane such as Tecothane®, which is commercially available from Hermedics Polymer Products, Wilmington, Mass. The one or more elastomeric components may provide the overall shape and flexibility of modular implantable medical device 201, while the non-elastomeric components may provide structural integrity for modular implantable medical device 201, restrict intermodule motion within modular implantable medical device 201 to certain ranges, and form a part of the lead interconnection modules 213. Further detail regarding reduction of intermodule motion within modular implantable medical devices may be found in a commonly-assigned U.S. Pat. No. 7,392,089 to Wahlstrand et al., entitled “REDUCING RELATIVE INTERMODULE MOTION IN A MODULAR IMPLANTABLE MEDICAL DEVICE.”



FIGS. 3A-3F are schematic diagrams illustrating various arrangements of multiple modules within a modular implantable medical device 301 according to various embodiments of the present invention. In each of these embodiments, modular implantable medical device 301 has three modules as discussed above in reference to FIG. 2: a control module 210, a power source module 211, and a recharge module 212. These modules may be arranged into a variety of configurations, including those illustrated, as long as any required interconnections needed between the modules, e.g., coupling modules, may be routed within the device. The various embodiments include triangular configurations, in such as those shown in FIGS. 3A-C, and inline configurations, such as those shown in FIGS. 3D-F. The set of lead connection devices 313 may be located in various locations within the device as well.


In some embodiments, such as those illustrated in FIGS. 3A-C and 3E-F, a member 322 at least partially encapsulates each of modules 210, 211 and 212. In other embodiments, such as that illustrated in FIG. 3D, at least one of the modules of modular IMD 301 is located outside of member 322. Module 212 located outside of member may, as shown in FIG. 3D, be tethered to member 322, allowing module 212 to be freely positioned some significant distance from member 322. Additional details relating to configurations of modules within a modular implantable medical devices and tethering of modules of an implantable medical device may be found in U.S. Patent Application Publication No. 2004/0176818 by Wahlstrand et al., entitled “MODULAR IMPLANTABLE MEDICAL DEVICE.”



FIGS. 4A-4C are schematic diagrams illustrating a member 422 of a modular implantable medical device 401. FIG. 4A illustrates that the modular implantable medical device 401 comprises a set of modules 410-412, and a set of motion reduction elements 421 within member 422, such as motion reduction fibers connecting modules 410 and 411. Modules 410 and 411 are also coupled by a coupling module 423.


Because member 422 and coupling module 423 are flexible, member 422 and coupling module 423 may not provide sufficient motion reduction for the modules 410-412. Specifically, excessive relative motion between modules 410 and 411 may compromise the structural integrity of coupling module 424, which may lead to failure of modular implantable medical device 401. Motion reduction elements 421 are used to provide sufficient structural integrity to the device 401 once implanted into the patient 100 by restricting relative motion between modules 410 and 411 to certain directions or within certain ranges. Additional details regarding motion reduction elements 421 are described in co-pending and commonly assigned U.S. Pat. No. 7,392,089 to Wahlstrand et al., entitled “REDUCING RELATIVE INTERMODULE MOTION IN A MODULAR IMPLANTABLE MEDICAL DEVICE.”



FIG. 4B illustrates that the member 422 may include two or more components, each component made of a different material. In particular, FIG. 4B illustrates the member 422 includes an elastomeric component 430 and a non-elastomeric component 431. The non-elastomeric component 431 is typically shaped to surround at least one of modules 410-412, i.e., is located proximate to sides of at least one of modules 410-412. In some embodiments, a plurality of individual non-elastomeric components 431 surround respective modules 410-412. In other embodiments, a non-elastomeric component 431 surrounds a plurality of modules 410-412 to integrate the surrounded modules in a common, semi-rigid structure.


The one or more non-elastomeric components 431 may be used to contain one or more modules within elastomeric component 430. Specifically, the one or more non-elastomeric components 431 may be formed to hold modules 410-412 within respective positions within elastomeric component 430. Elastomeric component 430 may, as shown in FIG. 4B, at least partially encapsulate each of modules 410-412 and provide an desired form factor for a modular implantable medical device. In some embodiments, non-elastomeric elements 431 are fitted into an elastomeric component 430 to form the member 422 before the electronic modules 410-412 are inserted into respective locations within member 422 where they will be contained by non-elastomeric elements 431.


Generally, member 422 provides a number of functions in including attaching to modules and other elements to provide a smooth interface surface for the device as it interacts with the patient, and protecting electrical connections and feed thru wires needed to connect modules to external leads.


Member 422 may be constructed from a durometric specific material to provide a clinically desirable device. In addition, a material used to construct the member 422 may possess a thermal conductivity characteristic to either act as a heat sink if needed to dissipate heat from modules 410-412, or a material to act as an insulator to shield the patient 100 from any excess heat from modules 410-412. Because the implantable medical device 401 may be constructed from a large number of modules to perform a desired task, the materials selected for used in constructing the member 422 may vary as needed by each embodiment.


In embodiments in which member 422 is constructed of components 431 and 432, the device 401 may be fabricated by integrating components 431 and 432 to form the member 422, constructing the modules 410-412 and their respective connection modules 423, and constructing any motion reduction elements 421. Once all of these components are fabricated, the motion restriction elements 421 may be combined with the member 422, and the interconnected modules 410-412 may be inserted into the member 422 into respective positions where they are contained by components 431.



FIG. 4C illustrates that the member 422 provides sloped interface 441 between the modules within the device 401 and the patient's body components. In embodiments in which the device 401 is implanted within tight spaces, such as under the scalp, the sloped interface 441 provides a smooth transition between the body and the device modules 410-412. Protrusions are known to cause possible stress points for tissue that is located over implanted devices, which can, for example, lead to skin erosion in the case of a device implanted under the scalp. As such, the sloped interface 441 attempts to minimize the transition from the modules 410-412 and the edge of the device 401 to eliminate these points of stress. An angle of interface 442 from the patient's body and the sloped interface 441 is greater than 90 degrees. Angle 442 may be between 120 and 150 degrees, is preferably between 130 and 140 degrees, and is most preferably approximately 135 degrees.



FIGS. 5A-5B are schematic diagrams illustrating the interaction of components of an implantable medical device that are part of a member. FIG. 5A provides a side cross-sectional view of a member 522 that includes an elastomeric component 530 and a non-elastomeric component 531 that interfaces with a control module 610. The non-elastomeric component 531 is shaped to mate with and surround the module 510, and may provide motion reduction for the module. Specifically, the non-elastomeric component 531 may be mechanically connected to at least one other module of a modular implantable medical device, e.g., to non-elastomeric components that surround other modules of an implantable medical device, by a motion reduction element 521. In other words, the member 522 encapsulates a plurality of modules in this embodiment, and each of the modules may be surrounded by a non-elastomeric component 531 that is connected to other non-elastomeric components by motion reduction elements 521.


A through hole 551 may be located through member 522, e.g., through elastomeric component 530 and non-elastomeric component 531, to provide an attachment point for the implantable medical device. In some embodiments, the implantable medical device may be secured in place using bone screws or similar attachment devices that secure the device to the patient. Such through holes 551 permit the device to be mechanically attached to the patient once the device is positioned at a desired location.


In addition, elastomeric component 530 is shown as completely encapsulating the modules and components within FIG. 5. However, in some embodiments, elastomeric component 530, like non-elastomeric component 531, may merely surround the module 510 but not cover the top of the module. Such an arrangement may render the profile of the overall device smaller. In such an alternate embodiment, a surface across the member and the electronics module 510 may minimize transition discontinuities to minimize profile changes that may interact with a patient after implantation. In other embodiments, one or both components 530 and 531 cover a top of module 510, or fully encapsulate module 510.



FIG. 5B illustrates a top view of the member 522 having an elastomeric component 530 that covers a non-elastomeric component 531 that surrounds the control module 510. The through hole 551 used as an attachment point is shown as part of the non-elastomeric component 531 that is covered by the elastomeric component 530. The shape of the non-elastomeric component 531 and control module 510 are shown as being rectangular in this embodiment. However, one skilled in the art will recognize that any shape for the non-elastomeric component 531 and control module 510 may be used without deviating from the spirit and scope of the present invention. Further, the shape of non-elastomeric component 531 need not be the same as that the shape of the component that it surrounds. The modules may be restrained within the member 522 using many restraint mechanisms known in the arts including attachment elements, adhesives, snap rings, and similar elements.


While the member 522 described above may be constructed from two different materials, a softer, more flexible elastomeric component 530 and one or more harder, more rigid non-elastomeric components 531, one skilled in the art may recognize that a member 522 may include a single component made of either class of material to provide the surface smoothing, module integration, and structural module restraint features described herein.


Finally, the member 522 may include several additional features unrelated to the above functions regarding the restraint and interconnection of multiple modules. In one embodiment, radio-opaque markers 561 and 562 may be imbedded within the member 522 to assist in determining an exact location of an implantable medical device within a patient. These radio-opaque markers 561 and 562 typically possess a non-symmetrical shape to permit registration and orientation of the device 501 from imaging of the markers. These radio-opaque markers may be constructed using barium and similar materials that permit such imaging. A telemetry and/or recharge coil may be embedded directly within the member 522.


It will be understood that an anti-infection agent and/or lubricious material may be disposed on or impregnated in at least a portion of an implantable medical device. A lubricious material is any material that when applied to an implantable medical device reduces the friction between the implantable medical device and the adjacent tissue. In one embodiment, the anti-infection agent and/or lubricious material may be disposed on or impregnated in the housing. For example, an anti-infection agent and/or lubricious material may be disposed on or impregnated in the housing 90 in FIG. 1A. In another embodiment, the anti-infection agent and/or lubricious material may be disposed on or impregnated in the member. For example, the anti-infection agent and/or lubricious material may be disposed on or impregnated in the member 94 in FIG. 1B. Disposing a lubricious material on or impregnated in a medical device may facilitate insertion of the device into the implantation location. The lubricious material may also reduce post-implant friction between a portion of the medical device and the adjacent tissue.


It may be desirable to apply the anti-infection agent and/or lubricious material to less than the entire outer surface of the device. In the case of an implant between the brain and scalp, the lubricious material may be disposed on the side of the device facing the scalp and therefore provide for easier insertion of the device under the scalp as well as reduce post implantation friction between the device and the scalp or other tissue. For example, in the case of device 90 when implanted between the brain and scalp, the convex side of the member 94 may be coated with a lubricious material 98 to reduce friction between the scalp and the device 90. The anti-infection agent may be applied to the concave side of the device.


Any known or future developed lubricious material, or combinations thereof, may be used. Preferably, the lubricious materials are medically suitable for inserting into a patient. Examples of suitable lubricous materials that may be disposed on at least a portion of a component of an implantable medical device include fluoroethylpolymer, polytetrafluoroethylene (PTFE), polyetheretherketone (PEEK), ethylene tetrafluoroethylene (ETFE), paralene, a hydrophilic polymer, and the like. Additional examples of suitable coating that may be applied include those described in the following patents and patent publications: US 20040030159; U.S. Pat. Nos. 6,558,734, 6,278,018; 6,603,040; 6,669,994; WO0121326; WO 0144174; and WO 2003055611. In an embodiment, the lubricious material is a hydrogel. The hydrogel may be a polyvinyl pyrrolidone (PVP) hydrogel, such as Medtronic's BIOGLIDE. In addition to facilitating insertion of a device, a lubricious material such as a hydrogel may prevent infection, thrombosis and formation of a fibrous capsule around the device. For example, BIOGLIDE technology has been shown to resist protein deposition, adherence of thrombosis, and reduce platelet and complement activation and may also inhibit tissue adherence.


Any known or future developed method for applying the anti-infection agent and/or lubricious material to either the housing or member may be utilized. In one embodiment, the lubricious material may be applied to the housing or member by being sprayed onto the surface of the housing or member. In another embodiment, the housing or member may be placed into the anti-infection agent and/or lubricious material allowing the anti-infection agent and/or lubricious material to be retained on or become impregnated in the housing or member.



FIG. 15 is a flowchart illustrating one embodiment method of fabricating an implantable medical device including a lubricious material on the housing of the module. In this method, the module or modules of the device 80 are fabricated at step 1500. At step 1502 a lubricious material is applied to at least a portion of the housing 82 or multiple housings of the device 80. It should be understood that the lubricious material may be applied to the housing either prior to assembly of the components within the housing or after such assembly. Moreover, when multiple modules are used, the lubricious material may be applied to the housings before or after coupling the modules to each other.



FIG. 16 is a flowchart illustrating another embodiment method of fabricating an implantable medical device including a lubricious material on a member. In this method, the member is fabricated at step 1600. The fabrication of the member can be by any known or future developed method. At step 1602, a module is fabricated. At step 1604, a lubricious material is applied to the member. The components including the member and module are combined at step 1604. As described with regard to the process of FIG. 15, assembly and application of the lubricious material may be performed in any order.


Additional techniques for applying an anti-infection agent are available. As discussed above, the anti-infection agent may be impregnated into the housing or member or it may be applied on the housing or member as a coating. Alternatively, the anti-infection agent may be incorporated into (via compounding or other methods) into a thin jacket, pouch, sleeve or thin cover that fits at least partially around the housing. For example, coating layer 86 in FIG. 1A or coating layer 98 in FIG. 1B (or any other coating of any of the implantable medical device embodiments) may be an anti-infection coating. Such coatings may be anti-infection agent, lubricious material or a combination lubricious material and anti-infection agent.


Any antimicrobial agent, such as an antibacterial agent, an antiseptic agent, etc., may be used to prevent infection. Non-limiting examples of antiseptics include hexachlorophene, cationic bisiguanides (i.e. chlorhexidine, cyclohexidine) iodine and iodophores (i.e. povidone-iodine), para-chloro-meta-xylenol, triclosan, furan medical preparations (i.e. nitrofurantoin, nitrofurazone), methenamine, aldehydes (glutaraldehyde, formaldehyde), silver sulfadiazine and alcohols. Nonlimiting examples of classes of antibiotics that may be used include tetracyclines (e.g. minocycline), rifamycins (e.g. rifampin), macrolides (e.g. erythromycin), penicillins (e.g. nafcillin), cephalosporins (e.g. cefazolin), other beta-lactam antibiotics (e.g. imipenem, aztreonam), aminoglycosides (e.g. gentamicin), chloramphenicol, sufonamides (e.g. sulfamethoxazole), glycopeptides (e.g. vancomycin), quinolones (e.g. ciprofloxacin), fusidic acid, trimethoprim, metronidazole, clindamycin, mupirocin, polyenes (e.g. amphotericin B), azoles (e.g. fluconazole) and beta-lactam inhibitors (e.g. sulbactam). Nonlimiting examples of specific antibiotics that may be used include those listed above, as well as minocycline, rifampin, erythromycin, nafcillin, cefazolin, imipenem, aztreonam, gentamicin, sulfamethoxazole, vancomycin, ciprofloxacin, trimethoprim, metronidazole, clindamycin, teicoplanin, mupirocin, azithromycin, clarithromycin, ofloxacin, lomefloxacin, norfloxacin, nalidixic acid, sparfloxacin, pefloxacin, amifloxacin, enoxacin, fleroxacin, temafloxacin, tosufloxacin, clinafloxacin, sulbactam, clavulanic acid, amphotericin B, fluconazole, itraconazole, ketoconazole, and nystatin.


An antimicrobial agent may be incorporated into or on the housing or member or a lubricious material using any known or future developed technique. For example, the antimicrobial agent may be disposed in or on the member or underlying coating layer (in one exemplary embodiment the underlying coating layer may be a lubricious material) through compounding or solvent expansion/swelling techniques. A hydrogel, for example, may be presoaked in a solvent comprising the anti-infection agent to incorporate the agent. Alternatively, an antimicrobial agent may be covalently attached to a housing or member or coating material using any known or future developed technology. Suitable technology includes Surmodic's PHOTOLINK technology. Conventional TDMAC (Tridodecylmethylammonium) coating technology, such as with TDMAC-heparin (Tridodecylmethylammonium heparinate), may also be employed. Additional technology for incorporating a therapeutic agent into or on a housing or member that may be used in accordance with the teachings of the present invention are discussed in, for example, U.S. Pat. Nos. 6,303,179, 6,143,354, 5,217,493, US 2004/0039437, and WO 04/014448. Of course any other therapeutic agent may be incorporated into or on the housing or member or lubricious coating.


As discussed above, another embodiment may utilize coating layers to apply the anti-infection agent to the housing or member. Depending upon the type of materials used to form coating layers, the coatings can be applied to the surface of the housing or member or an underlying coating layer through any coating processes known or developed in the art. One method includes directly bonding the coating material to a surface of the housing or member or underlying coating layer. By directly attaching a polymer coating to the housing or member or underlying coating layer, covalent chemical bonding techniques may be utilized. Housing or member or underlying coating layer surface may possess chemical functional groups on its surface such as carbonyl groups, primary amines, hydroxyl groups, or silane groups which will form strong, chemical bonds with similar groups on polymeric coating material utilized. In the absence of such chemical forming functional group, known techniques may be utilized to activate the material's surface before coupling the biological compound. Surface activation is a process of generating, or producing, reactive chemical functional groups using chemical or physical techniques such as, but not limited to, ionization, heating, photochemical activation, oxidizing acids, sintering, and etching with strong organic solvents. Alternatively, the coating layer may be indirectly bound to the member or housing or underlying coating layer through intermolecular attractions such as ionic or Van der Waals forces.


An anti-infection agent may also be incorporated into a coating layer in a variety of ways. For example, anti-infection agent may be covalently grafted to a polymer of the coating layer, either alone or with a surface graft polymer. Alternatively, an anti-infection agent may be coated onto the surface of the polymer or member either alone or intermixed with an overcoating polymer. An anti-infection agent may be physically blended with a polymer of a coating layer as in a solid-solid solution. Anti-infection agent may be impregnated into a polymer by swelling the polymer or member in a solution of the appropriate solvent. Any means of incorporating anti-infection agent into or on a coating layer may be used, provided that anti-infection agent may be released, leached or diffuse from coating layer, member or housing on contact with bodily fluid or tissue.


A polymer of a coating layer and an anti-infection agent may be intimately mixed either by blending or using a solvent in which they are both soluble. This mixture can then be formed into the desired shape or coated onto an underlying structure of the medical device. One exemplary method includes adding one or more anti-infection agents to a solvated polymer to form a anti-infection agent/polymer solution. The anti-infection agent/polymer solution can then be applied directly to the surface of a member (such as member 94 for example) or housing (such as housing 82), or an underlying coating layer (such as coating layer 98 or 86 for example); by either spraying or dip coating the housing or member. As the solvent dries or evaporates, the anti-infection agent/polymer coating is deposited on the member or housing. Furthermore, multiple applications can be used to ensure that the coating is generally uniform and a sufficient amount of anti-infection agent has been applied.


Alternatively, an overcoating polymer, which may or may not be the same polymer that forms the primary polymer of the member or underling coating layer 25, and anti-infection agent are intimately mixed, either by blending or using a solvent in which they are both soluble, and coated onto member or housing or underling coating layer. Any overcoating polymer may be used, as long as the polymer is able to bond (either chemically or physically) to the member or housing.


In addition, a polymer of a coating layer may be swelled with an appropriate solvent, allowing a anti-infection agent o impregnate the polymer.


Anti-infection agent may also be covalently grafted onto a polymer of a coating layer. This can be done with or without a surface graft polymer. Surface grafting can be initiated by corona discharge, UV irradiation, and ionizing radiation. Alternatively, the ceric ion method, previously disclosed in U.S. Pat. No. 5,229,172 (Cahalan et al.), may be used to initiate surface grafting.



FIG. 17 is a flowchart illustrating one embodiment method of fabricating an implantable medical device including an anti-infection agent on the housing of the module. In this method, the module or one or more modules of the device 80 are fabricated at step 1700. At step 1702 an anti-infection agent is applied to at least a portion of the housing 82 or multiple housings of the device 80. It should be understood that the anti-infection agent may be applied to the housing either prior to assembly of the components within the housing or after such assembly. Moreover, when multiple modules are used, the anti-infection agent may be applied to the housings before or after coupling the modules to each other.



FIG. 18 is a flowchart illustrating another embodiment method of fabricating an implantable medical device including an anti-infection agent on a member. In this method, the member is fabricated at step 1800. The fabrication of the member can be by any known or future developed method. At step 1802, a module is fabricated. At step 1804, an anti-infection agent is applied to the member. The components including the member and module are combined at step 1806. As described with regard to the process of FIG. 17, assembly and application of the anti-infection agent may be performed in any order.



FIG. 6 is a schematic diagram illustrating degrees of intermodular motion that may be present in modular implantable medical device. For any two modules within a distributed medical device, motion between the two modules may include pitch motion 601, yaw motion 602, and roll motion 603. For the set of motion reduction elements 621 discussed above, one or more of these three degrees of motion may be limited to prevent mechanical failures of interconnections between the modules during use of a modular implantable medical device. Specifically, modules of a modular implantable medical device may be connected by connector modules, which may be compromised by excessive intermodule motion. Such interconnect members are described in greater detail in commonly assigned U.S. Pat. No. 7,392,089 to Wahlstrand et al., entitled “REDUCING RELATIVE INTERMODULE MOTION IN A MODULAR IMPLANTABLE MEDICAL DEVICE.”



FIG. 7 is a schematic diagram illustrating motion reduction within various degrees of motion within a modular implantable medical device. For any two modules 701-702 within an implantable medical device, a connector module 721 may be used between the modules 701-702 to connect elements within these modules 701-702. Motion reduction elements 722 and 723 may be used to reduce inter-modular motion, and in some cases, to limit inter-modular motion to a range of motion.


Motion reduction elements 722 and 723 may be formed as part of non-elastomeric components 531 of a member 522 associated with each of modules 701 and 702. As shown in FIG. 7, motion reduction elements 722 and 723 allow free inter-modular motion within one of the degrees within a range. In some embodiments, one non-elastomeric component includes one or more motion reduction elements 722. In other embodiments, two non-elastomeric components 531 include motion reduction elements 722 and 723, respectively, which interact to reduce inter-modular motion.


A modular implantable medical device may include any number of motion reduction elements, which may take any of a variety of shapes. In some embodiments, motion reduction elements may be used in all axes to maximize the amount of motion reduction provided. The implantable medical device having multiple modules typically requires sufficient motion reduction to prevent undue mechanical stresses on interconnection connection member 721 between the modules 701-702 that may not be provided by a flexible member 522.


Additional details regarding the set of motion reduction elements 521 are described in co-pending and commonly assigned U.S. Pat. No. 7,392,089 to Wahlstrand et al., entitled “REDUCING RELATIVE INTERMODULE MOTION IN A MODULAR IMPLANTABLE MEDICAL DEVICE.”



FIG. 8A is a block diagram illustrating an example embodiment of a modular implantable medical device 801 having a tethered lead interconnect site 861 according to the present invention. A member 822 of implantable medical device 801 at least partially encapsulates and connects a plurality of modules 810-812 while not encapsulating lead connection modules 813 that are part of tethered lead interconnect site 861. In such embodiments, the implantation of device 801 would not require the insertion of external leads into the member 822. In addition, the external leads may be located a distance away from the device 801. Such an arrangement may assist in the management of the external leads as they are placed within the patient and routed to a device implantation location. Further, location of leads and connection site 861 away from member 822 may make it less likely that the leads will be damaged during a surgical explant procedure.


In alternate embodiments shown in FIGS. 8B-8C, member 822 may possess mechanical structures such as grooves 832, an externally attached pouch 833, or an integrated containment cavity 834 to contain and/or route the external leads away from the implantable medical device 801 in an efficient manner. In some embodiments, the external leads may possess a minimum length to provide a particular electrical characteristic for the implantable medical device 801. This minimum length may be greater than a distance needed by a particular patient for some implantation locations. These mechanical structures that assist in external lead management may accommodate any extra lead material that needs to be part of the device 801 in some implantation embodiments. Because the member may be spread over an area surrounding the modular device, the member may cover holes in the cranium formed to allow external leads to access the brain. Additional structures, including one or more cap structures 835 that secure a lead as it passes through the hole in the cranium may be an integral part of the member connector module 822.


Additional details regarding the lead connection modules are described in co-pending and commonly assigned U.S. Patent Application Publication No. 2004/0176816 by Singhal et al., entitled “LEAD CONNECTION MODULE OF A MODULAR IMPLANTABLE MEDICAL DEVICE.”



FIG. 9 is a block diagram illustrating an example embodiment of a modular implantable medical device 901 having an access loop 971 for removal according to the present invention. Access loop 971 may be mechanically coupled to, or formed as a part of member connector module 922. This access loop 971 may be used to assist in the removal of the implantable medical device 901 at a point in time when the device 901 is no longer needed by the patient, or at a point in time when a particular device 901 needs to be replaced. The device 901 may be encapsulated within the patient 100 with scar tissue fibers such that physical effort will be required to remove the device 901 from its implantation location. This access loop 971 provides a clinician a removal assist structure to physically manipulate the implantable medical device 901 during its removal. This access loop 971 may also be useful during implantation of the device 901 as well as it provides a handle to manipulate the device 901 without handing the member 922 and its related modules. One skilled in the art will recognize that alternate embodiments for the access loop that may include removal handles, a strip cord and a reinforced opening within the member connector module to provide a mechanism to grasp the device to assist in removal.



FIG. 10 is a schematic diagram illustrating an example embodiment of a modular implantable medical device 1001 having a triangular module arrangement according to the present invention. In this embodiment, a triangular arrangement of modules is shown with a member 1022 that at least partially encapsulates all of the modules. Lead interconnection modules 1013 are located between the modules at a common location. Member 1022 provides a slope interface 1041.



FIG. 11 is a schematic diagram illustrating an example embodiment of a modular implantable medical device 1101 having an inline module arrangement according to the present invention. In this embodiment, an inline arrangement of modules is shown with a member 1122 that at least partially encapsulates all of the modules. A lead interconnection module 1113 is located on one side of the member 1122. Member 1122 provides a slope interface 1141.



FIG. 12 is a schematic diagram illustrating side view of a multi-module implantable medical device having an inline module arrangement according to the present invention. The side view of the device 1201 shows an underside of the device 1202 that possess a curved shape to permit implantation at a location having a curved body structure.



FIG. 13 is a schematic diagram illustrating an exploded view of a modular implantable medical device 1301 having a triangular module arrangement according to the present invention. In this embodiment, yet another triangular arrangement of modules is shown with a member 1322 at least partially encapsulating all of the modules. A slope interface element 1341 is shown surrounding the member 1322. In this embodiment, the slope interface element 1341 is shown as a separate physical structure, such as a flexible band, an o-ring, removable flexible flange, or a tapered outer contour element that surrounds the member 1322, rather than a tapered portion of member 1322. Slope interface element 1341 provides a desired sloped interface between the edge of the implantable medical device and the patient. In some embodiments, the shape and contour of slope interface element 1341 may be modified at the time of implantation to obtain a desired shape, or slope interface elements 1341 may be selected at the time of implantation from a variety of slope interface elements to provide a desired slope interface for a particular patient.



FIG. 14 is a flowchart illustrating a method of constructing an implantable medical device with a member according to the present invention. An implantable medical device 401 may be fabricated by constructing the member 422 (1401) from a first and second component. As discussed above, member 422 may comprise two or more materials, and two or more components. For example, member may comprise one or more elastomeric components formed of an elastomeric material, such as silicone, and one or more non-elastomeric components formed of a non-elastomeric material. Once the member 422 is completed, the modules 410-412 with their respective connector modules 423 are constructed (1402). Next, any motion reduction elements 421 included in the device 401 are constructed. Once all of these components are fabricated, the motion restriction elements 421 may be combined with the member 422 (1403) and the interconnected modules 410-412 may be inserted (1404) into the member 422. From the combination of these components, the device 401 is formed.


It should be noted that the anti-infection agent and/or lubricious material may be on or impregnated in any of the embodiments of implantable medical devices provided even though such is not specifically called out in every Figure and accompanying description.



FIGS. 19A-19B are schematic diagrams illustrating an exemplary interaction of components of an IMD 1901. FIG. 19A provides a side view of an member 1922, which includes one or more soft or elastomeric components 1932 and one or more hard or non-elastomeric components 1931, which interface with a control module 1910. Non-elastomeric component 1931 may be shaped to mate with the module 1910 to provide motion restriction for the module. Non-elastomeric component 1931 may be mechanically connected to other modules using a motion restriction device (not shown). The member 1922 covers all of these components in this embodiment. A through hole 1951 may be located through the non-elastomeric component 1931 and elastomeric component 1932 to provide an attachment point for IMD 1901. In some embodiments, IMD 1901 may be anchored in place using bone screws or other anchoring devices. Through holes 1951 permit IMD 1901 to be mechanically anchored to the patient once the device 1901 is positioned at a desired location. In the embodiment shown in FIG. 19A, a bone screw inserted into through hole 1951 would seat against non-elastomeric component 1931, but the invention encompasses embodiments in which a bone screw would seat against another component, such as control module 1910.



FIG. 19B illustrates a top view of the device 1901 having elastomeric component 1932 of member 1922 covering the non-elastomeric components 1931 that frame control module 1910. The through hole 1951 used as an attachment point is shown as part of non-elastomeric component 1931 that is covered by elastomeric component 1932. The shape of non-elastomeric component 1931 and control module 1910 are shown as being rectangular in this embodiment. However, one skilled in the art will recognize that any shape for the non-elastomeric component 1931 and control module 1910 may be used without deviating from the spirit and scope of the present invention.


In both FIGS. 19A and 19B, a lead interconnect device 1952 is included within the non-elastomeric components 1931 of member 1922. In these examples, the non-elastomeric component 1931 restrains control module 1910 and external leads 1954, which are separate from lead interconnect device 1952. Typically, the external leads 1952 have iso-diametric proximal ends for connection of the external leads 1954 to IMD 1901. An external lead 1954 is inserted into the lead connection module in order to connect the external leads 1954 to electronics within control module 1910 of IMD 1901. This electrical connection from the control module 1910 to the external leads 1954 is made using a module connection lead wire 1956 that extends from control module 1910 and physically connects with the external lead 1954 within the lead connection module 1952.


The lead connection module 1952 may also include a mechanical lead securing mechanism 1958 that engages the external lead 1954 to restrain its motion and ensure electrical connection with feed-through wires 1956. In the embodiment of FIG. 19A, a tool 1960 is used to engage the mechanical lead securing mechanism 1958 within the lead connection module 1952. In this embodiment, the mechanical lead securing mechanism 1958 comprises a mechanical set-screw that is tightened by a screwdriver. An example of such a mechanical lead securing mechanism 1958 is a low-profile DBS lead extensions manufactured by Medtronic Inc. In alternate embodiments, the mechanical lead securing mechanism 1958 may be tool-less using a variety of known securing technologies that ensures the external lead 1954 does not separate from the lead connection module 1952. Tool-assisted or tool-less coupling of leads to the IMD both allow medical personnel to couple leads to the IMD quickly and securely.


The foregoing description of the exemplary embodiments of the invention has been presented for the purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many modifications and variations are possible in light of the above teaching. It is intended that the scope of the invention be limited not with this detailed description, but rather by the claims appended hereto.

Claims
  • 1. An implantable medical device comprising: a module comprising a housing that contains at least a portion of electronics for providing monitoring of or therapy to a brain of a patient;an anti-infection agent coated on or impregnated in at least a first portion of the housing; anda lubricious material coated on or impregnated in at least a second portion of the housing, wherein the first and second portions of the housing are different sides, and wherein at least one of the anti-infection agent or the lubricious material is only coated on or impregnated in one side of the housing.
  • 2. The implantable medical device of claim 1, wherein the module comprises a first module and the housing comprises a first housing, wherein the medical device further comprising a second module comprising a second housing, wherein the first and second modules are connected, and wherein the anti-infection agent is coated on or impregnated in the second housing.
  • 3. The implantable medical device of claim 1, wherein the anti-infection agent is only coated on or impregnated in one side of the housing.
  • 4. The implantable medical device of claim 1, wherein the housing comprises ceramic.
  • 5. The implantable medical device of claim 1, wherein the housing defines a substantially concave side that includes the first portion of the housing.
  • 6. The implantable medical device of claim 5, wherein the housing defines a substantially convex surface that includes the second portion of the housing.
  • 7. The implantable medical device of claim 1, wherein the lubricious material comprises a polymer layer and wherein the anti-infection agent is impregnated in the polymer layer and the polymer layer is attached to the at least the second portion of the housing.
  • 8. The implantable medical device of claim 1, wherein the lubricious material is electrically conductive.
  • 9. An implantable medical device comprising: a module comprising a housing that contains at least a portion of electronics for providing monitoring of or therapy to a patient;a member at least partially encapsulating the module, wherein the member provides a smooth interface between at least a portion of the housing and tissue of a patient;an anti-infection agent coated on or impregnated in a first portion of the member; anda lubricious material coated on or impregnated in at least a second portion of the member, wherein the first and second portions of the member are different sides, and wherein at least one of the anti-infection agent or the lubricious material is only coated on or impregnated in one side of the housing.
  • 10. The implantable medical device of claim 9, wherein the anti-infection agent is only coated on or impregnated in one side of the member.
  • 11. The implantable medical device of claim 10, wherein the member defines a substantially concave side comprising the first portion of the member.
  • 12. The implantable medical device of claim 11, wherein the anti-infection agent is only coated on or impregnated in the substantially concave side of the member.
  • 13. The implantable medical device of claim 10, wherein the member defines a substantially convex side comprising the second portion of the member.
  • 14. The implantable medical device of claim 13, wherein the lubricious material is only on the substantially convex side of the member.
  • 15. The implantable medical device of claim 9, wherein the member is flexible.
  • 16. The implantable medical device of claim 9, further comprising a lead connection module within the member for connecting an external lead to electronics within the module, wherein the external lead is separable from the lead connection module.
  • 17. The implantable medical device of claim 9, wherein an edge of the member provides a sloped interface with a surface of the patient, and an angle between the edge and the surface of the patient is greater than 90 degrees.
  • 18. The implantable medical device of claim 9, wherein the lubricious material is electrically conductive.
  • 19. An implantable medical device comprising: a module comprising a housing, wherein the housing contains at least a portion of electronics for providing monitoring of or therapy to a patient;anti-infection means coated on or impregnated in at least a first portion of the housing; andlubricious means coated on or impregnated in at least a second portion of the housing, wherein the first and second portions of the housing are different sides, and wherein at least one of the anti-infection means or the lubricious means is only coated on or impregnated in one side of the housing.
  • 20. The implantable medical device of claim 19, wherein the anti-infection agent is absent from at least one side of the housing.
  • 21. An implantable medical device comprising: a module comprising a housing, wherein the housing contains at least a portion of electronics for providing monitoring of or therapy to a patient;means for at least partially encapsulating the module, wherein the means for at least partially encapsulating the module provides a smooth interface between at least a portion of the housing and tissue of a patient;anti-infection means coated on or impregnated in at least a first portion of the means for at least partially encapsulating the module; andlubricious means coated on or impregnated in at least a second portion of the means for at least partially encapsulating the module, wherein the first and second portions of the means for at least partially encapsulating the module are different sides, and wherein at least one of the anti-infection means or the lubricious means is only coated on or impregnated in one side of the means for at least partially encapsulating the module.
  • 22. The implantable medical device of claim 21, wherein the means for at least partially encapsulating the module includes a substantially concave side comprising the first portion and a substantially convex side comprising the second portion.
  • 23. The implantable medical device of claim 22, wherein the anti-infection agent is only coated on or impregnated in the substantially concave side of the means for at least partially encapsulating the module.
  • 24. The implantable medical device of claim 22, wherein the lubricious material is only on the substantially convex side of the means for at least partially encapsulating the module.
  • 25. The implantable medical device of claim 21, wherein the module comprises a first module comprising a first housing, the implantable medical device further comprising a second module comprising a second housing, wherein the means for at least partially encapsulating the first module integrates the first and second module into a single structure and provides a smooth interface between the first and second housings and tissue of the patient.
  • 26. A method comprising: fabricating a module comprising a housing containing at least a portion of the electronics for providing monitoring of or therapy to a patient;applying an anti-infection agent to at least a first portion of the housing; andapplying a lubricious material to at least a second portion of the housing, wherein the first and second portions of the housing are different sides, and wherein at least one of the anti-infection agent or the lubricious material is only applied to one side of the housing.
  • 27. The method of claim 26, wherein applying an anti-infection agent to the at least the first portion of the housing comprises spraying an anti-infection agent onto the at least the first portion of the housing.
  • 28. The method of claim 26, wherein applying an anti-infection agent to the at least the first portion of the housing comprises placing the at least the first portion of the housing into the anti-infection agent.
  • 29. The method of claim 26, wherein applying an anti-infection agent to the at least the first portion of the housing comprises incorporating the anti-infection agent into a polymer layer and attaching the polymer layer to the at least the first portion of the housing.
  • 30. The method of claim 26, wherein applying an anti-infection agent to the at least the first portion of the housing comprises applying the anti-infection agent to only one side of the housing.
  • 31. A method comprising: fabricating a member configured to provide a smooth interface between an implantable medical device and tissue of a patient;fabricating a module containing at least a portion of the electronics for providing monitoring of or therapy to the patient;at least partially encapsulating the module with the member;applying a lubricious coating to at least a first portion of the member; andapplying an anti-infection agent to at least a second portion of the member, wherein the first and second portions of the member are different sides, and wherein at least one of the anti-infection agent or the lubricious material is only applied to one side of the member.
  • 32. The method of claim 31, wherein applying an anti-infection agent to the at least the first portion of the member comprises spraying an anti-infection agent onto the at least the first portion of the member.
  • 33. The method of claim 31, wherein applying an anti-infection agent to the at least the first portion of the member comprises placing the at least the first portion of the member into the anti-infection agent.
  • 34. The method of claim 31, wherein applying an anti-infection agent to the at least the first portion of the member comprises incorporating the anti-infection agent into a polymer layer and attaching the polymer layer to the at least the first portion of the member.
  • 35. The method of claim 34, wherein the polymer layer comprises the lubricious material.
  • 36. The method of claim 31, wherein applying an anti-infection agent to the at least the first portion of the member comprises compounding the anti-infection agent with the at least the first portion of the member.
  • 37. The method of claim 31, wherein applying an anti-infection agent to the at least the first portion of the housing comprises applying the anti-infection agent to only one side of the member.
  • 38. The method of claim 31, wherein applying a lubricious material to the at least the second portion of the housing comprises applying the lubricious material to only one side of the member.
Parent Case Info

This is a continuation of U.S. patent application Ser. No. 10/837,319 by Singhal et al., which was filed on Apr. 30, 2004 and published on Jan. 6, 2005 as U.S. Patent Application Publication No. 2005/0004620 and issued as U.S. Pat. No. 7,596,408 on Sep. 29, 2009, and is entitled, “IMPLANTABLE MEDICAL DEVICE WITH ANTI-INFECTION COATING.” U.S. patent application Ser. No. 10/837,319 is a continuation-in-part of U.S. patent application Ser. No. 10/730,873, filed Dec. 9, 2003, which issued as U.S. Pat. No. 7,242,982 to Singhal et al. on Jul. 20, 2007, is entitled “OVERMOLD FOR A MODULAR IMPLANTABLE MEDICAL DEVICE,” and in turn claims the benefit of: a. U.S. Provisional Application Serial No. 60/431,854, filed on Dec. 9, 2002, entitled “CRANIAL NEUROSTIMULATOR AND METHOD,” by Skime et al.;b. U.S. Provisional Application Serial No. 60/471,262, filed on May 16, 2003, entitled “IMPLANTABLE CRANIAL MEDICAL DEVICES AND METHODS,” by Wahlstrand et al.;c. U.S. Provisional Application Serial No. 60/503,945, filed on Sep 20, 2003, entitled “IMPLANTABLE CRANIAL MEDICAL DEVICES AND METHODS,” by Wahlstrand et al.;d. U.S. Provisional Application Serial No. 60/503,946, filed on Sep. 20, 2003, entitled “IMPLANTABLE CRANIAL MEDICAL DEVICES AND METHODS,” by Wahlstrand et al.; ande. U.S. Provisional Application Serial No. 60/507,857, filed on Oct. 1, 2003, entitled “THIN NEURO STIMULATION SYSTEM, DEVICE AND METHOD,” by Wahlstrand et al. Each of the preceding applications is incorporated herein by reference in its entirety. The following commonly-assigned U.S. patents and patent applications are also incorporated herein by reference: 1. U.S. Patent Application Publication No. 2004/0176818 by Wahlstrand et al., which was filed on Dec. 9, 2003 and published on Sep. 9, 2004, and is entitled “MODULAR IMPLANTABLE MEDICAL DEVICE”;2. U.S. Patent Application Publication No. 2004/0173221 by Singhal et al., which was filed on Dec. 9, 2003 and published on Sep. 9, 2004, and is entitled “IMPLANTATION OF LOW-PROFILE IMPLANTABLE MEDICAL DEVICE”;3. U.S. Pat. No. 7,392,089 to Wahlstrand et al., which issued on Jun. 24, 2008 and is entitled “REDUCING RELATIVE INTERMODULE MOTION IN A MODULAR IMPLANTABLE MEDICAL DEVICE”;4. U.S. Pat. No. 7,848,817 to Janzig et al., which was filed on Dec. 9, 2003 and issued on Dec. 7, 2010, and is entitled “COUPLING MODULE OF A MODULAR IMPLANTABLE MEDICAL DEVICE”;5. U.S. Patent Application Publication No. 2004/0176815 by Janzig et al., which was filed on Dec. 9, 2003 and published on Sep. 9, 2004, and is entitled “LOW-PROFILE IMPLANTABLE MEDICAL DEVICE”;6. U.S. Pat. No. 7,529,586 to Wahlstrand et al., which issued on May 5, 2009 and is entitled “CONCAVITY OF AN IMPLANTABLE MEDICAL DEVICE”;7. U.S. Patent Application Publication No. 2004/0176816 by Singhal et al., which was filed on Dec. 9, 2003 and published on Sep. 9, 2004, and is entitled “LEAD CONNECTION MODULE OF A MODULAR IMPLANTABLE MEDICAL DEVICE”;8. U.S. Pat. No. 7,212,864 to Wahlstrand et al., which issued on May 1, 2007 and is entitled “MODULAR IMPLANTABLE MEDICAL DEVICE”;9. U.S. Pat. No. 7,263,401 to Wahlstrand et al., which issued on Aug. 28, 2007 and is entitled “IMPLANTABLE MEDICAL DEVICE WITH A NONHERMETIC BATTERY”;10. U.S. Patent Application Publication No. 2005/0004637 by Singhal et al., which was filed on Apr. 29, 2004 and published on Jan. 6, 2005, and is entitled “EXPLANTATION OF IMPLANTABLE MEDICAL DEVICE”;11. U.S. Patent Application Publication No. 2005/0245806 by Singhal et al., which was filed on Apr. 29, 2004 and published on Nov. 3, 2005, and is entitled “IMPLANTATION OF IMPLANTABLE MEDICAL DEVICE”;12. U.S. Pat. No. 7,317,947 to Wahlstrand et al., which is entitled “HEADSET RECHARGER FOR CRANIALLY IMPLANTABLE MEDICAL DEVICE” and issued on Jan. 8, 2008; and13. U.S. Patent Application Publication No. 2005/0003268 by Scott et al., which was filed on Apr. 29, 2004 and published on Jan. 6, 2005, and is entitled “BATTERY HOUSING CONFIGURATION.”

US Referenced Citations (244)
Number Name Date Kind
3310051 Schulte Mar 1967 A
3522811 Schwartz et al. Aug 1970 A
3690325 Kenny Sep 1972 A
3720874 Gorcik et al. Mar 1973 A
3724467 Avery et al. Apr 1973 A
3888260 Fischell Jun 1975 A
3913587 Newash Oct 1975 A
3926198 Kolenik Dec 1975 A
3941135 von Sturm et al. Mar 1976 A
4006748 Schulman Feb 1977 A
4010760 Kraska et al. Mar 1977 A
4013081 Kolenik Mar 1977 A
4040412 Sato Aug 1977 A
4094321 Muto Jun 1978 A
4256115 Bilitch Mar 1981 A
4266552 Dutcher et al. May 1981 A
4328813 Ray May 1982 A
4399819 Cowdery Aug 1983 A
4399820 Wirtzfeld et al. Aug 1983 A
4408607 Maurer Oct 1983 A
4499907 Kallok et al. Feb 1985 A
4503860 Sams et al. Mar 1985 A
4574780 Manders Mar 1986 A
4616655 Weinberg et al. Oct 1986 A
4911178 Neal Mar 1990 A
4928696 Henderson et al. May 1990 A
4934368 Lynch Jun 1990 A
4969899 Cox, Jr. Nov 1990 A
4972846 Owens et al. Nov 1990 A
5085644 Watson et al. Feb 1992 A
5116345 Jewell et al. May 1992 A
5144946 Weinberg et al. Sep 1992 A
5197332 Shennib Mar 1993 A
5207218 Carpentier et al. May 1993 A
5218959 Fenster Jun 1993 A
5220929 Marquit Jun 1993 A
5243977 Trabucco et al. Sep 1993 A
5252090 Giurtino et al. Oct 1993 A
5271397 Seligman et al. Dec 1993 A
5312440 Hirschberg et al. May 1994 A
5314451 Mulier May 1994 A
5314453 Jeutter May 1994 A
5396813 Takeuchi et al. Mar 1995 A
5411538 Lin May 1995 A
H1465 Stokes Jul 1995 H
5431695 Wiklund et al. Jul 1995 A
5433734 Stokes et al. Jul 1995 A
5455999 Owens et al. Oct 1995 A
5456698 Byland et al. Oct 1995 A
5458997 Crespi et al. Oct 1995 A
5477855 Schindler et al. Dec 1995 A
5480416 Garcia et al. Jan 1996 A
5489225 Julian Feb 1996 A
5554194 Sanders Sep 1996 A
5562715 Czura et al. Oct 1996 A
5571148 Loeb et al. Nov 1996 A
5573551 Lin et al. Nov 1996 A
5613935 Jarvik Mar 1997 A
5638832 Singer et al. Jun 1997 A
5645586 Meltzer Jul 1997 A
5674260 Weinberg Oct 1997 A
5678559 Drakulic Oct 1997 A
5702430 Slimon et al. Dec 1997 A
5741313 Nason et al. Apr 1998 A
5755743 Volz et al. May 1998 A
5769874 Dahlberg Jun 1998 A
5776169 Schroeppel Jul 1998 A
5792067 Karell Aug 1998 A
5800535 Howard, III Sep 1998 A
5814095 Müller et al. Sep 1998 A
5836935 Ashton et al. Nov 1998 A
5843150 Adams et al. Dec 1998 A
5873899 Stutz, Jr. et al. Feb 1999 A
RE36120 Karell Mar 1999 E
5876424 O'Phelan et al. Mar 1999 A
5895414 Sanchez-Zambrano Apr 1999 A
5896647 Shkuratoff Apr 1999 A
5919215 Haeg et al. Jul 1999 A
5935154 Westlund Aug 1999 A
5941905 Single Aug 1999 A
5941906 Barreras, Sr. et al. Aug 1999 A
5954751 Chen et al. Sep 1999 A
5954757 Gray Sep 1999 A
5958088 Vu et al. Sep 1999 A
5984859 Lesinski Nov 1999 A
5991664 Seligman Nov 1999 A
6006124 Fischell et al. Dec 1999 A
6016449 Fischell et al. Jan 2000 A
6044304 Baudino Mar 2000 A
6061593 Fischell et al. May 2000 A
6067474 Schulman et al. May 2000 A
6091979 Madsen Jul 2000 A
6112120 Correas Aug 2000 A
6128538 Fischell et al. Oct 2000 A
6131581 Leysieffer et al. Oct 2000 A
6134474 Fischell et al. Oct 2000 A
6154677 Leysieffer Nov 2000 A
6162487 Darouiche Dec 2000 A
6168580 Yardley Jan 2001 B1
6176879 Reischl et al. Jan 2001 B1
6205358 Haeg et al. Mar 2001 B1
6214032 Loeb et al. Apr 2001 B1
6218016 Tedeschi et al. Apr 2001 B1
6230049 Fischell et al. May 2001 B1
6233488 Hess May 2001 B1
6248080 Miesel et al. Jun 2001 B1
6248126 Lesser et al. Jun 2001 B1
6259951 Kuzma et al. Jul 2001 B1
6263225 Howard, III Jul 2001 B1
6266556 Ives et al. Jul 2001 B1
6269266 Leysieffer Jul 2001 B1
6272382 Faltys et al. Aug 2001 B1
6283997 Garg et al. Sep 2001 B1
6308101 Faltys et al. Oct 2001 B1
6324428 Weinberg et al. Nov 2001 B1
6324433 Errico Nov 2001 B1
6330468 Scharf Dec 2001 B1
6354299 Fischell et al. Mar 2002 B1
6356792 Zonenshayn et al. Mar 2002 B1
6358281 Berrang et al. Mar 2002 B1
6360122 Fischell et al. Mar 2002 B1
6366813 DiLorenzo Apr 2002 B1
6405079 Ansarinia Jun 2002 B1
6415184 Ishikawa et al. Jul 2002 B1
6427086 Fischell et al. Jul 2002 B1
6436422 Trogolo et al. Aug 2002 B1
6445956 Laird et al. Sep 2002 B1
6456256 Amundson et al. Sep 2002 B1
6456886 Howard et al. Sep 2002 B1
6480743 Kirkpatrick et al. Nov 2002 B1
6490486 Bradley Dec 2002 B1
6498951 Larson et al. Dec 2002 B1
6505077 Kast et al. Jan 2003 B1
6516227 Meadows et al. Feb 2003 B1
6516808 Schulman Feb 2003 B2
6517476 Bedoya et al. Feb 2003 B1
6537200 Leysieffer et al. Mar 2003 B2
6554762 Leysieffer Apr 2003 B2
6560486 Osorio et al. May 2003 B1
6565503 Leysieffer et al. May 2003 B2
6567703 Thompson et al. May 2003 B1
6575894 Leysieffer et al. Jun 2003 B2
6597954 Pless et al. Jul 2003 B1
6618623 Pless et al. Sep 2003 B1
6626680 Ciurzynski et al. Sep 2003 B2
6648914 Berrang et al. Nov 2003 B2
6671544 Baudino Dec 2003 B2
6726678 Nelson et al. Apr 2004 B1
6736770 Leysieffer et al. May 2004 B2
6782292 Whitehurst Aug 2004 B2
6788974 Bardy et al. Sep 2004 B2
6805998 Jenson et al. Oct 2004 B2
6850802 Holsheimer Feb 2005 B2
6882881 Lesser et al. Apr 2005 B1
6899976 Larson et al. May 2005 B2
6963780 Ruben et al. Nov 2005 B2
6977124 Probst et al. Dec 2005 B2
6994933 Bates Feb 2006 B1
7010351 Firlik et al. Mar 2006 B2
7103415 Probst et al. Sep 2006 B2
7107097 Stern et al. Sep 2006 B2
7110819 O'Hara Sep 2006 B1
7212864 Wahlstrand et al. May 2007 B2
7242982 Singhal et al. Jul 2007 B2
7263401 Scott et al. Aug 2007 B2
7454251 Rezai et al. Nov 2008 B2
7596399 Singhal et al. Sep 2009 B2
7596408 Wahlstrand et al. Sep 2009 B2
7702380 Dean Apr 2010 B1
20010033953 Takeuchi et al. Oct 2001 A1
20010051819 Fischell et al. Dec 2001 A1
20020002390 Fischell et al. Jan 2002 A1
20020013612 Whitehurst Jan 2002 A1
20020019669 Berrang et al. Feb 2002 A1
20020042630 Bardy et al. Apr 2002 A1
20020042634 Bardy et al. Apr 2002 A1
20020051550 Leysieffer May 2002 A1
20020059049 Bradbury et al. May 2002 A1
20020068958 Bardy et al. Jun 2002 A1
20020072770 Pless Jun 2002 A1
20020077670 Archer et al. Jun 2002 A1
20020087201 Firlik et al. Jul 2002 A1
20020099412 Fischell et al. Jul 2002 A1
20020103510 Bardy et al. Aug 2002 A1
20020107546 Ostroff et al. Aug 2002 A1
20020147498 Tallarida et al. Oct 2002 A1
20020161403 Meadows et al. Oct 2002 A1
20020165588 Fraley et al. Nov 2002 A1
20020169485 Pless et al. Nov 2002 A1
20020177882 DiLorenzo Nov 2002 A1
20030004428 Pless et al. Jan 2003 A1
20030004546 Casey Jan 2003 A1
20030017372 Probst et al. Jan 2003 A1
20030040781 Larson et al. Feb 2003 A1
20030073972 Rosenman et al. Apr 2003 A1
20030085684 Tsukamoto et al. May 2003 A1
20030088294 Gesotti May 2003 A1
20030091893 Kishiyama et al. May 2003 A1
20030109903 Berrang et al. Jun 2003 A1
20030120320 Solom Jun 2003 A1
20030125786 Gliner et al. Jul 2003 A1
20030130706 Sheffield et al. Jul 2003 A1
20030171787 Money et al. Sep 2003 A1
20030204229 Stokes Oct 2003 A1
20040015070 Liang et al. Jan 2004 A1
20040030245 Noble et al. Feb 2004 A1
20040082977 Engmark et al. Apr 2004 A1
20040102828 Lowry et al. May 2004 A1
20040172090 Janzig et al. Sep 2004 A1
20040173221 Singhal et al. Sep 2004 A1
20040176673 Wahlstrand et al. Sep 2004 A1
20040176750 Nelson et al. Sep 2004 A1
20040176815 Janzig et al. Sep 2004 A1
20040176816 Singhal et al. Sep 2004 A1
20040176817 Wahlstrand et al. Sep 2004 A1
20040176818 Wahlstrand et al. Sep 2004 A1
20040176819 Wahlstrand et al. Sep 2004 A1
20040181263 Balzer et al. Sep 2004 A1
20040186528 Ries et al. Sep 2004 A1
20040243481 Bradbury et al. Dec 2004 A1
20050003268 Scott et al. Jan 2005 A1
20050004618 Scott et al. Jan 2005 A1
20050004619 Wahlstrand et al. Jan 2005 A1
20050004620 Singhal et al. Jan 2005 A1
20050004637 Singhal et al. Jan 2005 A1
20050033378 Sheffield et al. Feb 2005 A1
20050070971 Fowler et al. Mar 2005 A1
20050075679 Gliner et al. Apr 2005 A1
20050245806 Singhal et al. Nov 2005 A1
20050245984 Singhal et al. Nov 2005 A1
20060116743 Gibson et al. Jun 2006 A1
20060129205 Boveja et al. Jun 2006 A1
20060149336 Meadows Jul 2006 A1
20060184210 Singhal et al. Aug 2006 A1
20060184220 Singhal et al. Aug 2006 A1
20060195156 Singhal et al. Aug 2006 A1
20070074732 Singhal et al. Apr 2007 A1
20070185539 Singhal et al. Aug 2007 A1
20070255338 Wahlstrand et al. Nov 2007 A1
20080021511 Scott et al. Jan 2008 A1
20080065173 Wahlstrand et al. Mar 2008 A1
20090299164 Singhal et al. Dec 2009 A1
20090299165 Singhal et al. Dec 2009 A1
20090299380 Singhal et al. Dec 2009 A1
Foreign Referenced Citations (25)
Number Date Country
3940632 Dec 1990 DE
1 145 735 Oct 2001 EP
1 145 736 Oct 2001 EP
1 161 579 Aug 1969 GB
WO 9220402 Nov 1992 WO
WO 9906108 Feb 1999 WO
WO 9934758 Jul 1999 WO
WO 0013743 Mar 2000 WO
WO 0040295 Jul 2000 WO
WO 0110369 Feb 2001 WO
WO 0128622 Apr 2001 WO
WO 0139830 Jun 2001 WO
WO 0141858 Jun 2001 WO
WO 0160450 Aug 2001 WO
WO 0197906 Dec 2001 WO
WO 0205590 Jan 2002 WO
WO 02056637 Jul 2002 WO
WO 02083207 Oct 2002 WO
WO 02083208 Oct 2002 WO
WO 02083233 Oct 2002 WO
WO 03026739 Apr 2003 WO
WO 03076012 Sep 2003 WO
WO 2004043536 May 2004 WO
WO 2004052458 Jun 2004 WO
WO 2004052459 Jun 2004 WO
Related Publications (1)
Number Date Country
20090292327 A1 Nov 2009 US
Provisional Applications (5)
Number Date Country
60431854 Dec 2002 US
60471262 May 2003 US
60503945 Sep 2003 US
60503946 Sep 2003 US
60507857 Oct 2003 US
Continuations (1)
Number Date Country
Parent 10837319 Apr 2004 US
Child 12536258 US
Continuation in Parts (1)
Number Date Country
Parent 10730873 Dec 2003 US
Child 10837319 US